A fresh face joins the Giants’ outfield mix — and it’s already stirring some curiosity among fans.
SCOTTSDALE, Ariz. — The San Francisco Giants made news Sunday morning by signing outfielder Will Brennan to a one-year major league contract, adding another name to their growing outfield competition.
Brennan, who just turned 28, brings experience and grit from his four seasons with the Cleveland Guardians, where he played in 269 games and built a solid career batting line of .267/.307/.373 (90 OPS+), including 14 home runs and 19 stolen bases. Those aren’t superstar numbers — but they show steady production and versatility at the plate.
“We’ve had our eye on him for quite a while,” said Giants General Manager Zack Minasian. “He’s a grinder — plays hard, knows the strike zone, and can handle himself across the outfield, especially at the corners.” Minasian also noted that the team got enthusiastic feedback from Tony Vitello and Jayce Tingler, both familiar with Brennan’s background. “Everyone says great things about his character. We’re excited to welcome him into the group.”
But here’s where it gets interesting: Brennan’s road to this deal has been anything but smooth. Drafted in the eighth round in 2019 by Kansas State, he faced major setbacks last year, including Tommy John surgery in June to repair the UCL in his left elbow, followed by sports hernia surgery in September. Yet despite those back-to-back procedures, Minasian believes Brennan will be ready for full participation in spring camp. “We just want to be smart with his workload early on,” Minasian explained. “He’s past the hard part — it’s about managing the recovery, not holding him back.”
Defensively, Brennan has logged time at all three outfield spots, though right field has been his primary home with 198 games played there. Advanced metrics show mixed defensive results: -1 outs above average and -5 defensive runs saved over 1,766+ innings in the field. On offense, he’s a left-handed hitter who performs notably better against right-handers (.720 OPS) than lefties (.453 OPS). That split might influence how the Giants choose to use him.
In spring training, Brennan will be part of a lively competition with Jerar Encarnacion, Luis Matos, and Drew Gilbert for a backup outfield role. The roster mechanics add a layer of intrigue — both Encarnacion and Matos are out of minor league options, whereas Brennan and Gilbert still have options available. As Minasian put it, “It gives us more flexibility as we fine-tune the outfield group.”
To clear space for Brennan on the 40-man roster, the Giants shifted right-hander Rowan Wick to the 60-day injured list. Wick, who just signed a one-year deal with a club option for 2027, will miss the 2026 season while recovering from Tommy John surgery. His story is fascinating in its own right — he revived his career overseas with Japan’s Yokohama DeNA BayStars, where he was instrumental in their 2024 Japan Series championship and dominated in 2025 with a 0.84 ERA over 42 2/3 innings, striking out 49 hitters.
“We had scouts raving about what they saw in Japan,” Minasian noted. “Rowan was on our radar early. His numbers, his command, the data — it all pointed to someone who could really help us down the line.”
Wick’s signing also reflects a developing trend for the Giants: taking calculated risks on rehabbing pitchers with upside. Alongside Wick, the team also picked up left-hander Sam Hentges and right-hander Jason Foley this winter — both of whom are recovering from significant shoulder injuries. Hentges missed the entire 2025 season after surgeries on both shoulders, while Foley made only a handful of Triple-A appearances for Detroit before undergoing season-ending surgery last May.
Minasian sees these moves as a vote of confidence in the team’s medical and development systems. “We’ve built a really strong infrastructure — from the medical professionals to the technology at Scottsdale Stadium, Papago Park, and Oracle Park,” he said. “That gives us an edge in bringing players back healthy and maximizing their potential.”
But here’s the question fans might debate: Is this strategy of signing injured but promising talent a genius long-term play — or just a risky bet on potential recoveries? The Giants are clearly confident in their program, but some might argue they’re stacking too much hope on uncertain health.
What do you think — are the Giants wisely investing in upside, or gambling too heavily on medical miracles? Share your thoughts in the comments — this could get interesting.
